Massett, Matthew E.
Monaghan, Laura http://orcid.org/0000-0003-3669-4764
Patterson, Shaun
Mannion, Niamh
Bunschoten, Roderick P.
Hoose, Alex
Marmiroli, Sandra
Liskamp, Robert M. J.
Jørgensen, Heather G. http://orcid.org/0000-0003-4663-4191
Vetrie, David
Michie, Alison M.
Huang, Xu http://orcid.org/0000-0001-6706-199X
Funding for this research was provided by:
Adam Renwick Martin-Friends of Paul O’Gorman PhD Studentship
Carnegie Trust for the Universities of Scotland (PHD007721)
RCUK | Medical Research Council (1732414, 18048)
Chief Scientist Office (CGA/19/63)
Tenovus (S19-13)
Wellcome Trust (105614/Z/14/Z)
Leuka (2016/JGF/0005)
Friends of Paul O'Gorman Leukaemia Research Centre Howat Foundation
Article History
Received: 10 October 2020
Revised: 2 April 2021
Accepted: 6 April 2021
First Online: 3 June 2021
Ethics approval and consent to participate
: The use of human tissue was in compliance with the ethical and legal framework of the United Kingdom’s Human Tissue Act (2004) and the Human Tissue (Scotland) Act (2006). Normal CD34<sup>+</sup> mobilized HSPC surplus to requirements were from patients undergoing chemotherapy and autologous transplantation for lymphoma and myeloma. Their use was authorized by the Salford and Trafford Research Ethics Committee and, for samples collected since 2006, following the written informed consent of donors. Normal human BM was collected with informed consent from healthy adult male donors, with the ethical approval of the Yorkshire Independent Research Ethics Committee. Primary human AML samples were from Manchester Cancer Research Centre’s Tissue Biobank (instituted with approval of the South Manchester Research Ethics Committee) and Paul O’Gorman Leukaemia Research Centre’s hematological cell research biobank (with approval of the West of Scotland Research Ethics Committee 4). Their use was authorized following project review by the Research Tissue Biobank’s scientific sub-committee, and with the informed consent of donors.
: The authors declare no competing interests.